This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Editor's note: All this week, and into the start of next year, we'll be featuring reflections on 2018 from notable investors, entrepreneurs, and others from Southern California's technology community. What was the biggest news for your organization in 2018? You'll be able to browse all of those contributions here. Happy Holidays!
2018 was a year of ups and downs for the business and technology community. Storylines in various sectors helped shape the overall narrative in 2018. It was a year of big exits—both IPOs and acquisitions—for tech and life sciences companies. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
Once considered a passing phase, the concentration of capital into fewer, larger venture capital deals appears to be the new normal. 30 to more than $84 billion, according to the latest quarterly Venture Monitor report , which is produced by the National Venture Capital Association (NCVA) and PitchBook. That’s more.
In a post on Kik’s blog on Friday the MediaLab said that it has “finalized an agreement” to acquire Kik Messenger. “ Kik is one of those amazing places that brings us back to those early aspirations,” the blog post read. The company filed registration documents in California in June 2018.
Venture capital investments rose in 2018 to levels not seen since the heady days of 2000, the last year U.S. That’s according to PitchBook and the National Venture Capital Association’s Venture Monitor report, released this week, which tallied nearly 9,000 deals made last year, through which venture investors sunk $130.9
View the Slideshow On November 4-6, Xconomy organized a meeting of the minds—an elite gathering of leaders in technology, business, healthcare, education, and energy—to discuss and demonstrate the key trends in their fields, heading into next year.
The company built its own point-of-sale system and commerce APIs in-house, allowing them to deliver a “seamless” customer experience, former Glossier CTO Bryan Mahoney said in 2018. billion valuation from Lone Pine Capital, Sequoia, Forerunner Ventures and others.
One of the questions we discussed is, “How much capital should a startup raise?” ” Fred & I are both in agreement that there is a tension between capital constraints and creativity. Perhaps that’s rational capitalism at its extreme. Blogging is like Venus Fly Paper. This is classic Fred.
According to IPO research firm Renaissance Capital , 47 IPOs have priced so far this year across all sectors, down 27 percent compared to the same period in 2018. Five biotechs priced their IPOs and at least one more is coming. Just as last year, healthcare IPOs lead the way.
Privately held biotech ViaCyte has banked $27 million, the majority an installment of cash from a tranched $80 million Series D financing round it closed in late 2018.
The sector saw more big venture capital deals and acquisitions , while researchers kept plugging away on technology advances. software startups to reflect on the trends that defined the sector in 2018—and where things might be headed in 2019. It was an eventful year for the artificial intelligence industry. Meanwhile, A.I.
venture capital investments swelled to a level not seen since the dot-com era of the early 2000s. companies through the first six months of 2018, according to the latest Venture Monitor report produced quarterly by Seattle-based PitchBook and the National Venture Capital Association (NVCA). Last year, U.S. billion into U.S.
Venture capital investors poured more than $28.2 companies during the first three months of 2018—marking the strongest single quarter in at least a dozen years, according to the Venture Monitor Report released today by Seattle-based PitchBook and the National Venture Capital Association (NVCA). billion into U.S.
We love capital efficiency until we love land grabs until we abhor over funding until we get huge payouts and ring the bell for more funding until we attract every non-VC on the planet to invest in startups until it crashes and we start the cycle all over again none the wiser. blog here ). VC funding. I see it in many young pups.
After a breakout year in 2017, the blockchain sector suffered a series of blows in 2018, from crashing cryptocurrency prices to increased regulatory scrutiny of crypto ventures and deepening skepticism about whether the technology was actually useful.
Venture capital investors sank $547.2 million into 37 startup companies throughout San Diego County during the first three months of 2018, maintaining roughly the same level of venture funding seen in recent quarters, according to the Venture Monitor Report. It was almost 4 percent higher than the $526.7
René Pinnell says he and his wife Selena Pinnell were “blown away” by the virtual reality projects their friends were creating in 2014, so they looked for an entrepreneurial niche that would allow them to support such artists. That year the couple, both trained in design, founded a startup in San Francisco, then called KaleidoscopeVR.
Venture capital firms invest in potentially disruptive technologies with the hope of profit, then keep watch for further advances that could overtake their existing portfolio companies. All this is done while they guide startups through other external challenges such as fundraising droughts and overall market downturns.
She succeeds Greg McKee, who served as president and CEO of the San Diego-based organization for five years before stepping down last month to start a venture capital fund. She’s also a partner in Ad Astra Ventures, an accelerator and venture fund for women-led startups she started in 2018 with Allison Long Pettine and Vidya Dinamani.
billion in new capital Thursday as the company completed an IPO that set its market capitalization at $24.3 million shares at $72 apiece, according to Renaissance Capital —the top of a new range that Lyft originally set at $62 to $68. billion at the time of its last fundraising in mid-2018. Lyft sold 30.8
The San Diego biotech company, which is testing an antibody discovery platform intended to speed products to patients with cancer and pancreatitis, said Thursday it has retained a local investment banking firm, Objective Capital Partners, to guide its sale. million in the first nine months of 2018 and $22.8 As of Sept.
The San Diego-based biotech, which started operations about 18 months ago, made its public debut in December 2018 with $42 million. On Monday Erasca—a portmanteau of “erase” and “cancer”— announced it had completed a Series B financing round jointly led by Arch Venture Partners and Cormorant Asset Management.
Atomico, a European venture capital firm, has helped persuade Cambridge, UK-based Healx to return to the capital market a year earlier than anticipated. The biotech has just raised $56 million in Series B funding to bankroll its mission to use AI and machine learning to create affordable rare disease treatments.
This fall, we are convening exemplary business leaders, investors, and far-seeing technologists for an in-depth exploration of the innovation ecosystem and its impact on the future. Come join us at our newest interactive conference, XCON: The Xconomy Conference on Technology and Transformation.
million in seed—in 2018 to advance its growing suite of products, digitized. The team at Trust & Will, a San Diego-based startup founded in October of 2017, is betting that a good chunk of those people would shell out some money to outline an estate plan if the process were cheaper and easier.
When we have a chance to view it from a distance, the year 2018 may be seen as a period when innovations in a number of technological fields came together to transform not only the future of computing, but also the very structure of the Internet.
It’s early yet in 2018, but the current count could put life-sciences companies on pace to bust past last year’s $17.6 By our count, investors put more than $800 million into life-sciences startups in four days. The money came from a wide range of backers, not just traditional biotech venture firms. Elsewhere, the U.S.
Proceeds will be used to advance Metacrine’s lead drug candidate, MET409, into first-in-human studies during the first half of 2018. Initial studies should be completed by the end of the year, the San Diego-based company said.
Yet in 2018, perceptions about these dominant companies often reflected uneasiness and doubt—and for some, so did their stock performance. The market caps of some of the most successful tech titans reach as high as $1 trillion.
Facebook (NASDAQ: FB ) shares gained nearly 3 percent Tuesday, and ticked up further in after-hours trading following the release of a third quarter earnings report that showed some strengths as well as shortfalls. election campaigns.
Before you fly off, or drive, or simply unplug, check out our preview of what could be next year’s top clinical studies; the tumult in big pharma’s on again-off again relationship with consumer healthcare; big names on the move in the nation’s capital; and a flurry of year-end deals. Happy holidays, everyone.
Bain Capital and Pfizer (NYSE: PFE ) launched it in 2018 with neuroscience compounds from the pharma giant’s labs. If you’ve never heard of Arya (NASDAQ: ARYBU ), it’s a shell company that Perceptive Advisors formed specifically to serve as a vehicle to take a private company public. Cerevel is young, but it’s pretty far along.
But when the financial oversight council published its 2018 annual report, it concluded that volatility in the cryptocurrency. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
In 2018, my Exome colleagues and I published hundreds of stories about health, medicine, the biopharma industry, government policy, and more. You’ll find a few of our favorite stories in this review of some of the year’s best from across the Xconomy network.
As Xconomy’s editors looked back at the year just passed, we asked technology leaders to comment on the trends they’d observed in 2018, and the developments they expected in 2019.
In 2018, geopolitical events—in particular, President Donald Trump’s hard-line stances on trade and immigration, and the repeal of net neutrality rules—were top of mind for several business executives we interviewed recently.
From Portland to Pittsburgh, it’s likely that every city in the U.S. with more than 1 million people has made its case to Amazon to locate the company’s second headquarters there. At least, hopefully they have already, because today—if you haven’t heard—was the deadline to apply.
First it was street-style photography, then came the launch of her popular fashion blog WeWoreWhat. Bain Capital Ventures' Jamison Hill. The company plans to give creators and influencers more independence from existing platforms by allowing them access to funding from a team well-versed in their unique capital needs.
Amazon will pick the city in 2018. Amazon sent cities across North America into a frenzy Thursday after announcing plans to build a second headquarters outside of Seattle, bringing with it tens of thousands of jobs and billions of dollars in economic development benefits. Mexico is also part.
billion in 2018, and Novartis reportedly knew but failed to report it to the FDA before the agency approved Zolgensma in May. We learned last week that the FDA was investigating Novartis for manipulating animal data related to its $2 million-a-dose gene therapy Zolgensma. The activity took place at AveXis, the firm Novartis bought for $8.7
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content